Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04839380
What this trial is testing

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 49
Testing effectiveness (Phase 2)Looking for participantsNCT06773195
What this trial is testing

Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Who this might be right for
Myelofibrosis
Memorial Sloan Kettering Cancer Center 37
Early research (Phase 1)Not Yet RecruitingNCT07566897
What this trial is testing

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Who this might be right for
Renal Carcinoma MetastaticPancreatic Adenocarcinoma MetastaticPancreatic Adenocarcinoma+1 more
Philogen S.p.A. 96
Not applicableLooking for participantsNCT06627335
What this trial is testing

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Who this might be right for
Pregnancy RelatedAtopic Dermatitis
Incyte Corporation 5,621
Large-scale testing (Phase 3)Looking for participantsNCT06719024
What this trial is testing

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

Who this might be right for
Vitiligo
Hospital Authority, Hong Kong 20
Testing effectiveness (Phase 2)Study completedNCT05293717
What this trial is testing

Topical Ruxolitinib in Chronic Hand Dermatitis

Who this might be right for
Chronic Hand Dermatitis
University of Rochester 16
Testing effectiveness (Phase 2)Ended earlyNCT02420717
What this trial is testing

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT01423604
What this trial is testing

Study of Ruxolitinib in Pancreatic Cancer Patients

Who this might be right for
Pancreatic Cancer
Incyte Corporation 136
Testing effectiveness (Phase 2)WithdrawnNCT04354714
What this trial is testing

Ruxolitinib to Combat COVID-19

Who this might be right for
COVID-19
Washington University School of Medicine
Early research (Phase 1)Not Yet RecruitingNCT07801248
What this trial is testing

Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

Who this might be right for
Acute Skin Graft Versus Host Disease (GVHD)
Children's Hospital Medical Center, Cincinnati 10
Post-approval studies (Phase 4)Study completedNCT07368673
What this trial is testing

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

Who this might be right for
Vitiligo
Dow University of Health Sciences 120
Large-scale testing (Phase 3)Ended earlyNCT02117479
What this trial is testing

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Who this might be right for
Pancreatic Cancer
Incyte Corporation 321
Testing effectiveness (Phase 2)Looking for participantsNCT07249346
What this trial is testing

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Who this might be right for
LeukemiaMyelodysplasiaChronic Myelomonocytic Leukemia
Hannah Choe, MD 124
Early research (Phase 1)Ended earlyNCT01822756
What this trial is testing

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorsPancreatic Cancer
Incyte Corporation 42
Testing effectiveness (Phase 2)Study completedNCT01877005
What this trial is testing

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Lymphoma
The Lymphoma Academic Research Organisation 33
Large-scale testing (Phase 3)Study completedNCT02087059
What this trial is testing

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Who this might be right for
Primary Myelofibrosis (MF)
Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Looking for participantsNCT06378060
What this trial is testing

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Who this might be right for
Severe Aplastic Anemia
Hematology department of the 920th hospital 30
Not applicableStudy completedNCT05899725
What this trial is testing

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Who this might be right for
Severe Checkpoint Inhibitor Pneumonitis
Peking Union Medical College Hospital 60
Testing effectiveness (Phase 2)Study completedNCT04884191
What this trial is testing

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost- Essential Thrombocythemia Myelofibrosis
CTI BioPharma 165
Testing effectiveness (Phase 2)Active Not RecruitingNCT05622318
What this trial is testing

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Who this might be right for
Graft-versus-host Disease
Medical College of Wisconsin 56
Next Page